Literature DB >> 9034193

Control of telomere length by the human telomeric protein TRF1.

B van Steensel1, T de Lange.   

Abstract

Human telomeres, the nucleoprotein complexes at chromosome ends, consist of tandem arrays of TTAGGG repeats bound to specific proteins. In normal human cells, telomeres shorten with successive cell divisions, probably due to the terminal sequence loss that accompanies DNA replication. In tumours and immortalized cells, this decline is halted through the activation of telomerase, a reverse transcriptase that extends the telomeric TTAGGG-repeat arrays. Telomere length is stable in several immortal human-cell lines, suggesting that a regulatory mechanism exists for limiting telomere elongation by telomerase. Here we show that the human telomeric-repeat binding factor TRF1 (ref. 8) is involved in this regulation. Long-term overexpression of TRF1 in the telomerase-positive tumour-cell line HT1080 resulted in a gradual and progressive telomere shortening. Conversely, telomere elongation was induced by expression of a dominant-negative TRF1 mutant that inhibited binding of endogenous TRF1 to telomeres. Our results identify TRF1 as a suppressor of telomere elongation and indicate that TRF1 is involved in the negative feedback mechanism that stabilizes telomere length. As TRF1 does not detectably affect the expression of telomerase, we propose that the binding of TRF1 controls telomere length in cis by inhibiting the action of telomerase at the ends of individual telomeres.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9034193     DOI: 10.1038/385740a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  388 in total

1.  Progressive cis-inhibition of telomerase upon telomere elongation.

Authors:  S Marcand; V Brevet; E Gilson
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  TIN2, a new regulator of telomere length in human cells.

Authors:  S H Kim; P Kaminker; J Campisi
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

3.  Identification of two human nuclear proteins that recognise the cytosine-rich strand of human telomeres in vitro.

Authors:  L Lacroix; H Liénard; E Labourier; M Djavaheri-Mergny; J Lacoste; H Leffers; J Tazi; C Hélène; J L Mergny
Journal:  Nucleic Acids Res       Date:  2000-04-01       Impact factor: 16.971

4.  An anchorage nuclear structure for telomeric DNA repeats in HeLa cells.

Authors:  G Pierron; F Puvion-Dutilleul
Journal:  Chromosome Res       Date:  1999       Impact factor: 5.239

Review 5.  Crisis intervention: the role of telomerase.

Authors:  A J Lustig
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Molecular cytogenetics investigation of the telomeres in a case of Philadelphia positive B-ALL with a single telomere expansion.

Authors:  K Krejcí; J Stentoft; J Koch
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

7.  Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2.

Authors:  Katia Ancelin; Michele Brunori; Serge Bauwens; Catherine-Elaine Koering; Christine Brun; Michelle Ricoul; Jean-Patrick Pommier; Laure Sabatier; Eric Gilson
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

Review 8.  Natural and pharmacological regulation of telomerase.

Authors:  Jean-Louis Mergny; Jean-François Riou; Patrick Mailliet; Marie-Paule Teulade-Fichou; Eric Gilson
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

9.  Preferential maintenance of critically short telomeres in mammalian cells heterozygous for mTert.

Authors:  Yie Liu; Hue Kha; Mark Ungrin; Murray O Robinson; Lea Harrington
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

Review 10.  Telomerase: biological function and potential role in cancer management.

Authors:  V D Chatziantoniou
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.